Global Neurological Biomarkers Market 2016-2020

  • ID: 3846202
  • Report
  • Region: Global
  • 68 pages
  • TechNavio
1 of 5

FEATURED COMPANIES

  • AbaStar MDx
  • Acumen Pharmaceuticals
  • Alseres Pharmaceuticals
  • Banyan Biomarkers
  • Diagenic
  • Proteome Sciences
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

About Biomarkers

Biomarkers are the indicators considered for identifying specific diseases. They are mainly used for identification of the progress of a particular disease and evaluation of an effective method for drug target identification. The biomarkers specifically involved in the identification of the neurological disorders are called neurological biomarkers.

The analysts forecast the global neurological biomarkers market to grow at a CAGR of 15.48% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global neurological biomarkers market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of neurological biomarkers.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Neurological Biomarkers Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Myriad RBM
- Proteome Sciences
- QIAGEN
- Thermo Fisher Scientific

Other prominent vendors
- AbaStar MDx
- Abiant
- Acumen Pharmaceuticals
- Aepodia
- Alseres Pharmaceuticals
- Athena Diagnostics
- Banyan Biomarkers
- Cisbio Bioassays
- Diagenic
- Proteosys
- Psynova Neurotech

Market drivers
- Increasing focus toward drug discovery applications

Market challenges
- Unmet market needs of effective validation of biomarkers

Market trends
- Integrated biology approach will be the key focus area

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbaStar MDx
  • Acumen Pharmaceuticals
  • Alseres Pharmaceuticals
  • Banyan Biomarkers
  • Diagenic
  • Proteome Sciences
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
  • Biomarker assays kits
PART 05: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis:
PART 06: Market segmentation by indication
  • AD
  • PD
  • ASD
  • MS
PART 07: Market segmentation by application
  • Genomics-based biomarkers
  • Proteomics-based biomarkers
  • Metabolomics-based biomarkers
  • Imaging-based biomarkers
  • Emerging application areas
PART 08: Market segmentation by services
  • Services
PART 09: Market segmentation by end-user
  • Hospitals
  • Diagnostic and research laboratories
PART 10: Geographical segmentation
  • Neurological biomarkers market in Americas
  • Neurological biomarkers market in EMEA
  • Neurological biomarkers market in APAC
PART 11: Market drivers
  • Increasing low-cost clinical trials in developing countries
  • Growing personalized medicine for neurological disorders
  • Increasing focus toward drug discovery applications
PART 12: Impact of drivers

PART 13: Market challenges
  • Unmet market needs of effective validation of biomarkers
  • Reproducibility of biomarkers and tests leading to discrepancies
  • Delay in market launch
PART 14: Impact of drivers and challenges

PART 15: Market trends
  • Integrated biology approach will be the key focus area
  • Development of novel radiotracers for neuro biomarkers that aid diagnostic and clinical applications for diseases
  • Evolution of miRNA
PART 16: Vendor landscape
  • Competitive scenario
PART 17: Key vendor analysis
  • Geographic presence - Key vendor analysis
  • Myriad RBM
  • Proteome Sciences
  • QIAGEN
  • Thermo Fisher Scientific
  • Other prominent vendors
PART 18: Appendix
  • List of abbreviations
PART 19: About the Author

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Key biomarker technology platforms
Exhibit 03: Global neurological biomarkers market (2016-2020) ($ billions)
Exhibit 04: Five forces analysis
Exhibit 05: Market segmentation by indication
Exhibit 06: Market opportunities in the major indications
Exhibit 07: Global neurological biomarkers market segmentation by application 2015
Exhibit 08: Market opportunities in key applications
Exhibit 09: Impact mapping of neurological biomarker services
Exhibit 10: Opportunity analysis of biomarker services
Exhibit 11: Global neurological biomarkers market 2015
Exhibit 12: Market overview in Americas 2015
Exhibit 13: Neurological biomarkers market in Americas ($ billions)
Exhibit 14: Market overview in EMEA 2015
Exhibit 15: Neurological biomarkers market in EMEA ($ billions)
Exhibit 16: Market overview in APAC 2015
Exhibit 17: Neurological biomarkers market in APAC ($ millions)
Exhibit 18: Impact of drivers
Exhibit 19: Impact of drivers and challenges
Exhibit 20: Competitive structure analysis of global neurological biomarkers market 2015
Exhibit 21: Market penetration of key neurological biomarkers manufacturers 2015
Exhibit 22: Strategic success factors of companies in global neurological biomarkers market
Exhibit 23: Regional analysis of key vendors
Exhibit 24: Myriad RBM: Profile
Exhibit 25: Myriad RBM: Strength analysis
Exhibit 26: Myriad RBM: Growth strategy matrix
Exhibit 27: Myriad RBM: Opportunity assessment analysis
Exhibit 28: Proteome Sciences: Profile
Exhibit 29: Proteome Sciences: Strength analysis
Exhibit 30: Proteome Sciences: Growth strategy matrix
Exhibit 31: Proteome Sciences: Opportunity assessment
Exhibit 32: QIAGEN: Profile
Exhibit 33: QIAGEN: Strength analysis
Exhibit 34: QIAGEN: Growth strategy matrix
Exhibit 35: QIAGEN: Opportunity assessment
Exhibit 36: Thermo Fisher Scientific: Profile
Exhibit 37: Thermo Fisher Scientific: Strength analysis
Exhibit 38: Thermo Fisher Scientific: Growth strategy matrix
Exhibit 39: Thermo Fisher Scientific: Growth opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbaStar MDx
  • Acumen Pharmaceuticals
  • Alseres Pharmaceuticals
  • Banyan Biomarkers
  • Diagenic
  • Proteome Sciences
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

New Report Released: - Global Neurological Biomarkers Market 2016-2020

The author of the report recognizes the following companies as the key players in the global neurological biomarkers market: Myriad RBM, Proteome Sciences, QIAGEN, and Thermo Fisher Scientific.

Other Prominent Vendors in the market are: AbaStar MDx, Abiant, Acumen Pharmaceuticals, Aepodia, Alseres Pharmaceuticals, Athena Diagnostics, Banyan Biomarkers, Cisbio Bioassays, Diagenic, Proteosys, and Psynova Neurotech.

Commenting on the report, an analyst from the research team said: “Integrated biology approach will be the key focus area and a key trend for market growth. Single-cell biosensors have already been developed for protein and DNA biomarkers. The development of nanosensors, which can be used for neuro-based analytes, is expected to emerge. For example, BRAF tests for neuropathology is under research. Software like Genedata Expressionist that can integrate and analyze data from different omics platforms and deliver meaningful clinical biomarkers will be the next focus. Systems Biology approaches will enter into routine use for biomarker validation, pre-clinical drug development, and clinical trials (virtual patients) in the next 4-5 years. Multi-marker blood-based tests that can diagnose and differentiate between closely related neurodegenerative disorders will be a critical emerging area.”

According to the report, one of the key drivers for market growth will be increasing focus toward drug discovery applications. Close to 1% of medications in the biomarker discovery and development pipeline achieve the commercial success. The rate of failure cases is too high, and very frequently drug candidates fail in the late development phase. This has led to the evolution of alternative biomarker-based techniques by contract research organizations and manufacturers.

Further, the report states that unmet market needs will be a challenge for the market. The inability to give convincing proof regarding the clinical and financial advantages of introducing new biomarker-based diagnosis methods are recognized as the main challenge for moderate uptake of new biomarkers. Genuine limitations, such as reproduction of positive clinical trial result, the absence of early pre-analytical examinations, the absence of autonomous check of results, and failure of investigators to assess whether the use of the biomarker would improve clinical practice to the benefit of neuro patients are hindering diagnostic neurological biomarker validation. Innovative evaluation of fluid-based proteomics enables biomarkers identification as indicators of the onset of neurological disease have been complex and incurs high research cost.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

- Myriad RBM
- Proteome Sciences
- QIAGEN
- Thermo Fisher Scientific
- AbaStar MDx
- Abiant
- Acumen Pharmaceuticals
- Aepodia
- Alseres Pharmaceuticals
- Athena Diagnostics
- Banyan Biomarkers
- Cisbio Bioassays
- Diagenic
- Proteosys
- Psynova Neurotech
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll